RC
MGX icon

RBF Capital’s Metagenomi Therapeutics MGX Stock Holding History

RBF Capital’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.8K Hold
64,021
– – ﹤0.01% 480
2025
Q4 		$104K Sell
64,021
-6,759
-10% -$14.6K ﹤0.01% 538
2025
Q3 		$168K Sell
70,780
-9,220
-12% -$18.7K 0.01% 535
2025
Q2 		$118K Buy
+80,000
New +$125K 0.01% 563

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RBF Capital's MGX Position: Q1 2026 in Review

RBF Capital held its Metagenomi Therapeutics (MGX) position steady in Q1 2026 at 64,021 shares worth $85.8K. The position accounts for ﹤0.01% of the portfolio, ranked #480.

RBF Capital first reported a position in MGX in Q2 2025 and has held it in 4 quarters since. The position peaked at $168K in Q3 2025. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • RBF Capital held 64,021 shares of Metagenomi Therapeutics worth $85.8K as of Q1 2026.
  • RBF Capital left its Metagenomi Therapeutics share count unchanged in Q1 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of RBF Capital's portfolio in Q1 2026, its #480 holding.
  • RBF Capital first reported a position in Metagenomi Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • RBF Capital's Metagenomi Therapeutics position peaked at $168K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on RBF Capital's 13F filing for Q1 2026, filed 15 May 2026.